Which ppi is best

Lassen AT. Acid-related disorders and use of antisecretory medication. Dan Med Bull. Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol. Klotz U. Pharmacokinetic considerations in the eradication of Helicobacter pylori. Clin Pharmacokinet.

Safety of proton pump inhibitors. Med Clin Barc ; — Review article: the clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther. An open-label, parallel, multiple-dose study comparing the pharmacokinetics and gastric acid suppression of rabeprazole extended-release with esomeprazole 40 mg and rabeprazole delayed-release 20 mg in healthy volunteers. Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials.

Curr Med Res Opin. Review article: the pharmacology of rabeprazole. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med. Update on the pharmacogenomics of proton pump inhibitors. Wolfe MM, Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome.

Howden CW. Optimizing the pharmacology of acid control in acid-related disorders. Tolerance to oral H2-receptor antagonists. Dig Dis Sci. The effectiveness of ranitidine in reducing gastric acid-secretion decreases with continued therapy.

Br J Clin Pharmacol. Optimizing acid suppression for treatment of acid-related diseases. Omeprazole and H2-receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis: a meta-analysis. Eur J Gastroenterol Hepatol. Rates of duodenal ulcer DU healing by drug classes: a meta-analysis. Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer.

Prakash A, Faulds D. Fitton A, Wiseman L. Pantoprazole: a review of its pharmacological properties and therapeutic use in acid-related disorders. Omeprazole 20 mg three days a week and 10 mg daily in prevention of duodenal ulcer relapse: double-blind comparative trial. Prevention of duodenal ulcer recurrence with 15 mg lansoprazole: a double-blind placebo-controlled study. The Lansoprazole Study Group.

Efficacy of continuous therapy for peptic ulcer in controlled clinical trials. Prognostic factors in upper gastrointestinal bleeding. Laine L, Jensen DM. Management of patients with ulcer bleeding. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Consensus recommendations for managing patients with nonvariceal upper gastrointestinal bleeding.

Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. Cochrane Database Syst Rev. Endoscopic therapy for bleeding ulcers: an evidence-based approach based on meta-analyses of randomized controlled trials. Clin Gastroenterol Hepatol. Laine L, Peterson WL.

Bleeding peptic ulcer. N Engl J Med. Marshall BJ. Helicobacter pylori. Nihon Rinsho. Optimum duration of regimens for Helicobacter pylori eradication. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases. J Am Pharm Assoc Wash ; 40 — Changes of gastric mucosal architecture during long-term omeprazole therapy: results of a randomized clinical trial. Changing patterns of Helicobacter pylori gastritis in long-standing acid suppression.

Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. Long-term proton pump inhibitor administration worsens atrophic corpus gastritis and promotes adenocarcinoma development in Mongolian gerbils infected with Helicobacter pylori. Long-term proton pump inhibitor administration, H pylori and gastric cancer: lessons from the gerbil. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: a meta-analysis.

Wallace JL. Read the Issue. Sign Up Now. Previous: Newsletter. Next: The Safety of Caffeine Consumption. Nov 1, Issue. From left: Dr. Mark Graber, Dr. Andrea Darby-Stewart, and Dr. Robert Dachs. Purpose Each month, three presenters will review an interesting journal article in a conversational manner. Is one PPI better than another?

What does this article say? Six studies of lansoprazole Prevacid 30 mg versus omeprazole 20 mg found no difference. Two studies of rabeprazole Aciphex 20 mg versus omeprazole 20 mg found no difference. Should we believe this study? What should the family physician do? Read the full article. Get immediate access, anytime, anywhere. Choose a single article, issue, or full-access subscription. Earn up to 6 CME credits per issue. Purchase Access: See My Options close.

Best Value! Proton pump inhibitors are approved for use in children over 1-year of age and are dosed based on weight. Use of PPIs in children may result in an increased risk of infections like pneumonia and a stomach infection caused by the organism C.

Proton pump inhibitors may also increase the risk of fractures in children. Therefore, these medications are not generally given to children unless first consulting with a healthcare provider. However, because use of a proton pump inhibitor in infants is not approved by the U. Food and Drug Administration FDA , it is up to the discretion of your healthcare provider to decide the need. Because long-term use of PPIs can increase the risk of C.

In fact, the Beers List of potentially inappropriate medications for older adults recommends no more than eight weeks of continued use in adults over the age of Auromedics Pharma LLC: Voluntary recall of pantoprazole 40mg for Injection due to presence of glass particles in the vial , December Do not take proton pump inhibitors if you have a history of a hypersensitivity reaction to any proton pump inhibitor.

Except for esomeprazole , proton pump inhibitors should be avoided in patients who are also taking products containing rilpivirine. Because small amounts of these drugs can pass into breast milk, nursing mothers should talk to their healthcare providers before using a proton pump inhibitor.

Proton pump inhibitors are generally well-tolerated. However, there are some common side effects that may occur, such as headache, constipation, diarrhea, and upset stomach. More serious side effects that require immediate medical attention are as follows:. Proton pump inhibitors are available in OTC and prescription form.

Internal Clinical Guidelines T. Dyspepsia and gastro-oesophageal reflux disease: investigation and management of dyspepsia, symptoms suggestive of gastro-oesophageal reflux disease, or both. Clinical guideline update Katz, P. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Grant, A. Minimal access surgery compared with medical management for gastro-oesophageal reflux disease: five year follow-up of a randomised controlled trial REFLUX.

Dellon, E. ACG clinical guideline: Evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis EoE. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Hershcovici, T.

Pharmacological management of GERD: where does it stand now? Trends Pharmacol Sci. Laine, L. Aliment Pharmacol Ther. Ohara, S. A double-blind, controlled study comparing lafutidine with placebo and famotidine in Japanese patients with mild reflux esophagitis.

J Gastroenterol. Pilotto, A. Comparison of four proton pump inhibitors for the short-term treatment of esophagitis in elderly patients. World J Gastroenterol. Kobeissy, A. A randomized open-label trial of on-demand rabeprazole vs ranitidine for patients with non-erosive reflux disease.

Cho, Y. Efficacy of pantoprazole 20 mg compared with pantoprazole 40 mg in the treatment of reflux esophagitis: a randomized, double-blind comparative trial. Dig Dis Sci. Tan, V. Treatment of non-erosive reflux disease with a proton pump inhibitor in Chinese patients: a randomized controlled trial.

Dabholkar, A. The month safety profile of dexlansoprazole, a proton pump inhibitor with a dual delayed release formulation, in patients with gastro-oesophageal reflux disease. Peura, D. Clinical trial: lansoprazole 15 or 30 mg once daily vs. Xia, X. Gastroenterol Res Pract. Sigterman, K. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.

Cochrane Database Syst Rev. Naci, H. Circulation: Cardiovascular Quality and Outcomes. Abel, C. Dexlansoprazole in the treatment of esophagitis and gastroesophageal reflux disease. Ann Pharmacother. Lundh, A. Industry sponsorship and research outcome. Salanti, G. A case study of multiple-treatments meta-analysis demonstrates that covariates should be considered.

J Clin Epidemiol. Higgins, J. The Cochrane Collaboration, , Available from www. Accessed Oct 1, Gerhard, T. Bias: considerations for research practice. Am J Health Syst Pharm.

Dias, S. Study designs to detect sponsorship and other biases in systematic reviews. Piepho, H. Multiplicative interaction in network meta-analysis. Statistics in Medicine. Flacco, M. Head-to-head randomized trials are mostly industry sponsored and almost always favor the industry sponsor.

Journal of Clinical Epidemiology. Madan, J. Consistency between direct and indirect trial evidence: is direct evidence always more reliable? Value Health.

Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods. Xiong, T. Overall similarity and consistency assessment scores are not sufficiently accurate for predicting discrepancy between direct and indirect comparison estimates. Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials.

Med Decis Making. Jansen, J. Puhan, M. Ades, A. Bayesian methods for evidence synthesis in cost-effectiveness analysis. Evidence synthesis for decision making 3: heterogeneity—subgroups, meta-regression, bias, and bias-adjustment. Mavridis, D. Addressing missing outcome data in meta-analysis. Evid Based Ment Health.

Abraha, I. Deviation from intention to treat analysis in randomised trials and treatment effect estimates: meta-epidemiological study. Chaimani, A. Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions. Res Synthesis Methods. Short-term treatment of gastroesophageal reflux disease. J Gen Intern Med. Lu, G.

Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. Brooks, S. Alternative methods for monitoring convergence of iterative simulations.

J Comput Graph Stat. Google Scholar. Greco, T.